The first 60 days: Chromophobe renal cell carcinoma
Chromophobe kidney cancer comes from a different cell of the kidney's tubules, usually behaves gently and is cured by surgery. Its rare metastatic form responds poorly to immunotherapy, so kinase and mTOR inhibitors are used, and it runs in families with Birt-Hogg-Dube syndrome. Below, week by week, is what OnCo's record of Chromophobe renal cell carcinoma says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Localised.
- RadiologistNamed in the standard of care for: Birt-Hogg-Dube syndrome.
- SurgeonNamed in the standard of care for: Localised, Birt-Hogg-Dube syndrome.
- Medical oncologistNamed in the standard of care for: Localised, Metastatic.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Partial nephrectomy or ablation; active surveillance for small tumours; no adjuvant therapy.
Sunitinib, cabozantinib, everolimus or lenvatinib plus everolimus; immunotherapy has low response rates outside sarcomatoid disease; trials preferred.
Kidney surveillance with MRI, nephron-sparing surgery at 3 cm, and genetic counselling.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Multiple whole-chromosome losses, TP53 and PTEN mutations, CK7 and KIT positive, distinguishing it from oncocytoma, Germline FLCN testing when syndromic features are present), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Classic chromophobe, Eosinophilic chromophobe, Birt-Hogg-Dube-associated.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Localised
- For my situation (localised), which of the standard options do you recommend and why?Guideline options include: Partial nephrectomy or ablation; active surveillance for small tumours; no adjuvant therapy.
Metastatic
- For my situation (metastatic), which of the standard options do you recommend and why?Guideline options include: Sunitinib, cabozantinib, everolimus or lenvatinib plus everolimus; immunotherapy has low response rates outside sarcomatoid disease; trials preferred.
- Am I a candidate for Sunitinib, Cabozantinib, Everolimus or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Birt-Hogg-Dube syndrome
- For my situation (birt-hogg-dube syndrome), which of the standard options do you recommend and why?Guideline options include: Kidney surveillance with MRI, nephron-sparing surgery at 3 cm, and genetic counselling.
Any stage
- Are there clinical trials I could join, for example of Lenvatinib, Everolimus?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “No randomised trial has ever been run in chromophobe cancer”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Immunotherapy rarely works and the reason is not understood”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Chromophobe renal cell carcinoma: the full pageChromophobe kidney cancer comes from a different cell of the kidney's tubules, usually behaves gently and is cured by surgery. Its rare metastatic form responds poorly to immunotherapy, so kinase and mTOR inhibitors are used, and it runs in families with Birt-Hogg-Dube syndrome.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.